• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.

作者信息

Quan Joshua, Ma Christopher, Panaccione Remo, Hracs Lindsay, Sharifi Nastaran, Herauf Michelle, Markovinović Ante, Coward Stephanie, Windsor Joseph W, Caplan Léa, Ingram Richard J M, Charlton Carmen, Kanji Jamil N, Tipples Graham, Holodinsky Jessalyn K, Bernstein Charles N, Mahoney Douglas J, Bernatsky Sasha, Benchimol Eric I, Kaplan Gilaad G

机构信息

Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, AB, Canada.

Department of Medicine, Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Calgary, Calgary, AB, Canada; Alberta Precision Laboratories, Public Health Laboratory, Calgary, AB, Canada.

出版信息

Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1077-1079. doi: 10.1016/S2468-1253(22)00340-5. Epub 2022 Oct 26.

DOI:10.1016/S2468-1253(22)00340-5
PMID:36306801
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9597523/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2a1/9597523/151acf8ea238/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2a1/9597523/151acf8ea238/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2a1/9597523/151acf8ea238/gr1_lrg.jpg

相似文献

1
Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.炎症性肠病患者对前四剂严重急性呼吸综合征冠状病毒2疫苗的血清学反应。
Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1077-1079. doi: 10.1016/S2468-1253(22)00340-5. Epub 2022 Oct 26.
2
Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.炎症性肠病患者对三剂严重急性呼吸综合征冠状病毒2疫苗接种的血清学反应。
Gut. 2023 Apr;72(4):802-804. doi: 10.1136/gutjnl-2022-327440. Epub 2022 May 23.
3
Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.炎症性肠病患者对 SARS-CoV-2 疫苗接种的细胞和体液免疫反应。
J Crohns Colitis. 2022 Sep 8;16(9):1347-1353. doi: 10.1093/ecco-jcc/jjac048.
4
Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study.免疫抑制和生物治疗的炎症性肠病患者的 SARS-CoV-2 疫苗接种的疗效和安全性：前瞻性观察研究。
PLoS One. 2022 Sep 2;17(9):e0273612. doi: 10.1371/journal.pone.0273612. eCollection 2022.
5
Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy.接受抗TNF治疗的炎症性肠病儿科患者对BNT162b2新冠病毒疫苗的抗体反应。
Gut. 2022 Sep;71(9):1922-1924. doi: 10.1136/gutjnl-2021-326196. Epub 2021 Nov 23.
6
Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.加拿大安大略省炎症性肠病患者中 SARS-CoV-2 疫苗第三剂的接种情况。
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):288-289. doi: 10.1016/S2468-1253(22)00054-1. Epub 2022 Feb 23.
7
Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.接受静脉生物治疗的炎症性肠病患者对新冠病毒疫苗的接种率下降。
Lancet Gastroenterol Hepatol. 2022 Nov;7(11):984-985. doi: 10.1016/S2468-1253(22)00302-8. Epub 2022 Sep 22.
8
COVID-19 mRNA Vaccine Short-Term Safety in Patients With Inflammatory Bowel Disease.炎症性肠病患者中COVID-19 mRNA疫苗的短期安全性
Gastroenterology. 2022 Mar;162(3):987-988. doi: 10.1053/j.gastro.2021.10.004. Epub 2021 Oct 6.
9
SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: correspondence.炎症性肠病患者使用不同生物制剂时的 SARS-CoV-2 疫苗接种：通信。
Rev Esp Enferm Dig. 2023 Sep;115(9):531. doi: 10.17235/reed.2023.9347/2022.
10
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases.炎症性肠病患者对 SARS-CoV-2 疫苗加强剂量的强烈反应。
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1881-1883.e1. doi: 10.1016/j.cgh.2022.01.056. Epub 2022 Feb 9.

引用本文的文献

1
Durability of Antibody Responses to SARS-CoV-2 Vaccination over 12 Months in Pediatric Inflammatory Bowel Disease.儿童炎症性肠病中SARS-CoV-2疫苗接种后12个月抗体反应的持久性
Vaccines (Basel). 2025 May 22;13(6):549. doi: 10.3390/vaccines13060549.
2
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.新型冠状病毒肺炎与炎症性肠病实用最新进展：新型冠状病毒肺炎疾病风险及疫苗安全性与有效性
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):88-97.
3
Immunization of children with inflammatory bowel disease against SARS-CoV-19 infection: A prospective single centre cohort study.

本文引用的文献

1
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.在SARS-CoV-2大流行的奥密克戎毒株浪潮期间，接受英夫利昔单抗治疗的炎症性肠病患者出现疫苗逃逸、突破性感染增加和再次感染的情况。
Gut. 2023 Feb;72(2):295-305. doi: 10.1136/gutjnl-2022-327570. Epub 2022 Jul 28.
2
Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).在加拿大阿尔伯塔省接种疫苗后的时期（2021 年 3 月至 2021 年 7 月）对 SARS-CoV-2 的血清阳性率。
Infect Dis (Lond). 2022 Sep;54(9):666-676. doi: 10.1080/23744235.2022.2080250. Epub 2022 May 31.
3
炎症性肠病患儿接种新冠病毒疫苗预防SARS-CoV-19感染：一项前瞻性单中心队列研究。
Vaccine X. 2023 Aug 19;15:100374. doi: 10.1016/j.jvacx.2023.100374. eCollection 2023 Dec.
4
The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD.2023年炎症性肠病对加拿大的影响：COVID-19与炎症性肠病
J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S76-S82. doi: 10.1093/jcag/gwad019. eCollection 2023 Sep.
Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.
炎症性肠病患者对三剂严重急性呼吸综合征冠状病毒2疫苗接种的血清学反应。
Gut. 2023 Apr;72(4):802-804. doi: 10.1136/gutjnl-2022-327440. Epub 2022 May 23.
4
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.英夫利昔单抗和维得利珠单抗治疗的炎症性肠病患者接种两剂 SARS-CoV-2 疫苗后的抗体衰减、T 细胞免疫和突破性感染。
Nat Commun. 2022 Mar 16;13(1):1379. doi: 10.1038/s41467-022-28517-z.
5
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases.炎症性肠病患者对 SARS-CoV-2 疫苗加强剂量的强烈反应。
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1881-1883.e1. doi: 10.1016/j.cgh.2022.01.056. Epub 2022 Feb 9.
6
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.炎症性肠病（IBD）免疫抑制患者 COVID-19 疫苗诱导的抗体反应（VIP）：一项多中心、前瞻性、病例对照研究。
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):342-352. doi: 10.1016/S2468-1253(22)00005-X. Epub 2022 Feb 4.
7
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2.接种SARS-CoV-2 mRNA疫苗mRNA-1273和BNT162b2后3个月和6个月时IBD患者的体液免疫反应
Biomedicines. 2022 Jan 13;10(1):171. doi: 10.3390/biomedicines10010171.
8
Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.炎症性肠病成年患者接种SARS-CoV-2 mRNA疫苗后的抗体反应
Ann Intern Med. 2021 Dec;174(12):1768-1770. doi: 10.7326/M21-2483. Epub 2021 Oct 12.
9
Immunity to SARS-CoV-2 variants of concern.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）关注变异株的免疫力。
Science. 2021 Mar 12;371(6534):1103-1104. doi: 10.1126/science.abg7404.
10
Effect of IBD medications on COVID-19 outcomes: results from an international registry.IBD 药物对 COVID-19 结局的影响：来自国际注册研究的结果。
Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20.